Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Alzheimer's Disease

    San Francisco, CA

    Search
    Alzheimer's Disease
    San Francisco, CA
    Show Map
    Map View
    San Francisco, CA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      46 Alzheimer's Disease Trials near San Francisco, CA

      Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      [18F]PI-2620 PET Imaging for Alzheimer's Disease

      San Francisco, California
      This trial tests a brain scan that uses a special substance to detect harmful proteins in people with Alzheimer's disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Aggressive Treatment, Brain Lesions, Others
      Must Not Be Taking:Amyloid, Tau Therapies

      200 Participants Needed

      Donanemab for Alzheimer's Disease

      San Francisco, California
      This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:65 - 80

      Key Eligibility Criteria

      Disqualifiers:Mild Cognitive Impairment, Dementia, Cancer, Others
      Must Not Be Taking:Cognitive Enhancers

      2996 Participants Needed

      Donanemab for Early Alzheimer's Disease

      San Francisco, California
      This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:MRI/PET Contraindication, Others
      Must Not Be Taking:Immunoglobulin G Therapy

      1736 Participants Needed

      VY7523 for Alzheimer's Disease

      San Francisco, California
      This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Stroke, Seizures, Schizophrenia, Cancer, Others
      Must Be Taking:Acetylcholinesterase Inhibitors

      52 Participants Needed

      MK-2214 for Alzheimer's Disease

      San Francisco, California
      Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Stroke, Seizures, CNS Disease, Others
      Must Not Be Taking:Biologics, Immunosuppressants

      340 Participants Needed

      E2814 + Lecanemab for Alzheimer's Disease

      San Francisco, California
      The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Neurological Conditions, Stroke, Seizures, Others
      Must Be Taking:Acetylcholinesterase Inhibitors

      105 Participants Needed

      Brain Health Assessment for Dementia

      San Francisco, California
      The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Hospice Care
      Must Not Be Taking:Dementia Medications

      1350 Participants Needed

      EAAT2 PET Tracer for Dementia

      San Francisco, California
      This trial tests a new imaging agent that can be seen with a PET scan to detect early brain changes in patients with Alzheimer's disease and frontotemporal dementia. The agent targets a specific brain protein that is less active in these diseases. By identifying these changes early, doctors hope to improve diagnosis and treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:40 - 75

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breast-feeding, Claustrophobia, Others
      Must Not Be Taking:CNS Drugs, Nicotine Cessation

      102 Participants Needed

      Music Activities for Dementia

      San Francisco, California
      This is an exploratory mixed-methods control-treatment study to evaluate if participation in rhythmic musical activities improves social attention and connectedness in individuals living with mild to moderate bvFTD and AD, and their caregivers. Secondary objectives include evaluating the potential relationships between brain networks associated with rhythm production, social attention, and connectedness in these populations.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:55 - 89

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Severe Diabetes, Others
      Must Not Be Taking:Antidepressants

      80 Participants Needed

      BIIB080 for Alzheimer's Disease

      San Francisco, California
      In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. * Clinicians use the CDR-SB to measure several categories of dementia symptoms. * The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of BIIB080. The study will be split into 2 parts. The 1st part is the Placebo-Controlled Period. The 2nd part is the Long-Term Extension (LTE) Period. The 2nd part of the study will help researchers learn about the long-term safety of BIIB080, and how it affects the participant's daily life, thinking, and memory abilities in the longer term. A description of how the study will be done is given below. * After screening, participants will first receive either a low dose or high dose of BIIB080, or a placebo, as an injection into the fluid around the spinal cord (cerebrospinal fluid). A placebo looks like the study drug but contains no real medicine. * Participants will receive BIIB080 or placebo once every 12 weeks or 24 weeks. * After 76 weeks of treatment in the Placebo-Controlled Period, eligible participants will move onto the Extension Treatment period, which will last 96 weeks. * In the extension period, participants who received placebo will be switched to high dose BIIB080 every 12 or 24 weeks. * Participants may be in the study for up to 201 weeks, or about 4 years. This includes the screening and follow-up periods. * Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. * After the screening period, most participants will visit the clinic every 6 weeks.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Allergy To BIIB080, Unstable AD Meds, MRI Contraindications, Others
      Must Not Be Taking:Anti-amyloid Antibodies

      416 Participants Needed

      18F-OP-801 for ALS

      San Francisco, California
      This trial tests a new brain scan substance called 18F-OP-801 on patients with ALS, AD, MS, PD, and healthy volunteers. It helps doctors see brain inflammation by highlighting active immune cells. This could improve early detection and treatment of these diseases.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Obesity, Alcoholism, Drug Abuse, Others
      Must Not Be Taking:Corticosteroids, NSAIDs

      65 Participants Needed

      BMS-986446 for Early Alzheimer's Disease

      San Francisco, California
      This trial is testing a new medication called BMS-986446 in people with early Alzheimer's disease. The medication is designed to target harmful proteins in the brain to slow down the disease. Researchers are checking if it works well and is safe for patients.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Other Cognitive Conditions, MRI Contraindications, Others

      310 Participants Needed

      Tau Tracer Comparison for Alzheimer's Disease

      San Francisco, California
      This trial uses special imaging agents to help visualize harmful brain proteins in people at risk of Alzheimer's disease. The agents make these proteins glow during scans, allowing doctors to see them clearly and monitor the disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Pregnant, Breastfeeding, Cognitive Impairment, Others

      822 Participants Needed

      Neuromodulation for Primary Progressive Aphasia

      San Francisco, California
      The goal of this clinical trial is to learn whether remotely-supervised transcranial direct-current stimulation (RS-tDCS) can improve speech and language treatments for individuals with logopenic variant primary progressive aphasia (lvPPA). tDCS is a form of brain stimulation where a low-level electrical current is delivered to the brain through electrodes placed on the head. The main questions the trial aims to answer are: * Is it feasible to do RS-tDCS with virtual speech therapy? * How can brain magnetic resonance imaging scans (MRIs) predict how well someone will benefit from RS-tDCS with virtual speech therapy? Researchers will compare active RS-tDCS stimulation to sham stimulation (where there is no active stimulation, but participants feel stimulation effects at the beginning and end of the session). Participants will: * Travel to either the University of California, San Francisco (UCSF) or the University of Texas at Austin (UT Austin) one time for in-person testing, an MRI scan, and training on how to use the RS-tDCS equipment * Meet with a speech-language pathologist for pre-treatment testing on Zoom for 2 weeks * Participate in speech-language therapy and independent practice on Zoom 5 days a week for 4 weeks, using either active tDCS stimulation or sham * Complete post-treatment testing on Zoom for 1-2 weeks * Complete follow-up testing 2 months after completion of treatment

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      80 Participants Needed

      Brain Beta-Amyloid for Postoperative Cognitive Dysfunction

      San Francisco, California
      Postoperative cognitive decline (POCD) affects up to 50% of non-cardiac surgical patients greater than or equal to 65 years of age. This study will test the hypothesis that preoperative presence of brain beta-amyloid plaques in non-demented subjects increases postoperative cognitive decline (POCD) in elderly subjects scheduled for hip or knee replacement. The investigators hypothesize that preoperative beta-amyloid plaques will predict postoperative cognitive decline.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Severe Psychiatric Disorders, Dementia, Others

      66 Participants Needed

      Speech Therapy + tDCS for Aphasia

      San Francisco, California
      This trial aims to help people with primary progressive aphasia (PPA) by combining home-based brain stimulation with online speech therapy. The brain stimulation uses a gentle electrical current to boost the effects of speech therapy, which may improve communication skills and quality of life for those affected by PPA.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Stroke, Epilepsy, Brain Injury, Others

      10 Participants Needed

      Care Ecosystem for Dementia

      San Francisco, California
      The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by unlicensed Care Team Navigators, who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. The evidence base to date suggests that the Care Ecosystem improves outcomes important to people with dementia, caregivers, and payers when delivered in a controlled research environment, including reduced emergency department visits, higher quality of life for patients, lower caregiver depression, and reduced potentially inappropriate medication use (Possin et al., 2019; Liu et al., 2022). The investigators propose a rapid pragmatic trial in 6 health systems currently offering the Care Ecosystem program in geographically and culturally diverse populations. The investigators will leverage technology, delivering care via the phone and web and using electronic health records to monitor quality improvements and evaluate outcomes while maximizing external validity. The investigators will evaluate the effectiveness of the Care Ecosystem on outcomes important to patients, caregivers, healthcare providers, and health systems during the pandemic. By evaluating the real-world effectiveness in diverse health systems that are already providing this model of care, this project will bridge the science-practice gap in dementia care during an unprecedented time of heightened strain on family caregivers, healthcare providers and health systems.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-progressive Dementia, Prior Program Enrollment, Others

      2550 Participants Needed

      Screening for Alzheimer's Disease Studies

      Oakland, California
      This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Neurological Conditions, CNS Trauma, Others

      13000 Participants Needed

      Computerized Cognitive Tests for Early Detection of Alzheimer’s Disease

      Berkeley, California
      The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests. These tests are designed to permit the early detection of individuals at risk of age-related cognitive decline.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Disorder, Stroke, Substance Abuse, Others

      2000 Participants Needed

      KarXT for Alzheimer's-Related Psychosis

      Lafayette, California
      This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Major Depression, Others

      400 Participants Needed

      Why Other Patients Applied

      "I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

      EK
      Mild Cognitive Impairment PatientAge: 72

      "I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

      OF
      Alzheimer's Disease PatientAge: 65

      "I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

      WU
      Healthy Volunteer PatientAge: 76

      "I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

      VL
      Alzheimer's PatientAge: 71

      "I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

      AH
      Dementia PatientAge: 64
      Match to a Alzheimer's Disease Trial

      KarXT for Alzheimer's-Related Psychosis

      Lafayette, California
      This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027, CN012-0056 or CN012-0034. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study, 14-week CN012-0056 or 14 week CN012-0034 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT and KarXT + KarX-EC in subjects with psychosis associated with Alzheimer's Disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Severe Medical Conditions, Others

      800 Participants Needed

      Precision Medicine for Dementia

      San Rafael, California
      The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia. Precision medicine approach starts with the completion of many tests and then the study doctor uses the test results to carefully prepare a treatment plan that is best for the individual person to help treat many of the underlying causes of mild cognitive impairment or early-stage dementia. The main question the study aims to answer is: • Does the precision medicine approach improve memory (cognitive function) better than the current standard-of-care treatment in people with mild cognitive impairment or early-stage dementia during a 9-month treatment period? This is a randomized clinical trial which means that a group of people that meet the study requirements will be assigned at random or by chance (like toss of a coin) to receive either the precision medicine treatment or the current gold standard (standard-of-care). People assigned to the precision medicine group will receive precision medicine for 9-months while those assigned to the standard-of-care group will follow that approach for 9-months, followed by an opportunity to receive up to six months of precision medicine, if desired. Participants will be asked to: * Have their blood drawn for extensive lab testing and collect urine and stool samples as well * Carefully follow instructions received from their study doctor and study team * Make lifestyle changes as prescribed by the study doctor and study team based on your precision medicine program * Take supplements and medications prescribed by the study doctor. * Once officially in the study (after meeting study entry or screening requirements), participate in ten (10) monthly visits with the study doctor, and other members of the study team as scheduled. * Complete cognitive tests at scheduled visits during the study * Have a study partner with you during visits and to help support you on the program Researchers will compare test results between the two study groups to see if the precision medicine approach improves those tests results over the time of the study, resulting in the improvement of cognition over a 9-month treatment period.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:45 - 76

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Type 1 Diabetes, Others
      Must Be Taking:Aricept

      72 Participants Needed

      AR1001 for Alzheimer's Disease

      Burlingame, California
      This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Delirium, Schizophrenia, Cancer, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      1535 Participants Needed

      KarXT for Alzheimer's-Associated Psychosis

      Lafayette, California
      This trial is testing KarXT, a medication, to see if it can prevent psychotic symptoms from returning in people with Alzheimer's Disease. It works by balancing brain chemicals that cause hallucinations and delusions. KarXT has shown positive results in reducing symptoms of schizophrenia.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Severe Renal Impairment, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      380 Participants Needed

      AVP-786 for Alzheimer's-related Agitation

      Lafayette, California
      This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Non-Alzheimer's Dementia, Unstable Systemic Diseases, Myasthenia Gravis, Others

      241 Participants Needed

      Xanomeline + Trospium for Agitation in Alzheimer's Disease

      Walnut Creek, California
      The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Schizoaffective, Others
      Must Not Be Taking:MAO Inhibitors, Anticonvulsants, Mood Stabilizers, Tricyclics

      352 Participants Needed

      KarXT + KarX-EC for Alzheimer's Disease

      Walnut Creek, California
      The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Pulmonary, Renal, Others

      600 Participants Needed

      AXS-05 for Alzheimer's Disease Agitation

      Walnut Creek, California
      The primary objective of this open-label extension trial is to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 and ACCORD-2.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:65 - 90

      Key Eligibility Criteria

      Disqualifiers:Hospitalized, Nursing Home, Living Alone, Others

      150 Participants Needed

      Senicapoc for Alzheimer's Disease

      Walnut Creek, California
      This trial tests Senicapoc, a drug that may reduce brain inflammation, in patients with early-stage Alzheimer's disease. The goal is to see if it can slow down memory loss and other symptoms by protecting brain cells.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Unstable Illnesses, Psychiatric Illness, Drug Abuse, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      55 Participants Needed

      ONO-2020 for Alzheimer's Disease

      Walnut Creek, California
      This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Stroke, Schizophrenia, HIV, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      240 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Alzheimer's Disease clinical trials in San Francisco, CA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Alzheimer's Disease clinical trials in San Francisco, CA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials in San Francisco, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Francisco, CA for Alzheimer's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Francisco, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Alzheimer's Disease medical study in San Francisco, CA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Alzheimer's Disease clinical trials in San Francisco, CA?

      Most recently, we added Vagus Nerve Stimulation for Aging, Neuromodulation for Primary Progressive Aphasia and KarXT + KarX-EC for Alzheimer's Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in California

      Anxiety Clinical Trials in California

      Schizophrenia Clinical Trials in California

      ADHD Clinical Trials in California

      Bipolar Disorder Clinical Trials in California

      Multiple Sclerosis Clinical Trials in California

      Autism Clinical Trials in California

      Treatment Resistant Depression Clinical Trials in California

      Borderline Personality Disorder Clinical Trials in California

      Social Anxiety Disorder Clinical Trials in California

      Parkinson's Disease Clinical Trials in California

      Alzheimer's Disease Clinical Trials in California

      By Location

      Clinical Trials near Los Angeles, CA

      Clinical Trials near San Francisco, CA

      Clinical Trials near San Diego, CA

      Clinical Trials near Sacramento, CA

      Clinical Trials near La Jolla, CA

      Clinical Trials near Orange, CA

      Clinical Trials near Stanford, CA

      Clinical Trials near Palo Alto, CA

      Clinical Trials near Long Beach, CA

      Clinical Trials near Duarte, CA

      Clinical Trials near Oakland, CA

      Clinical Trials near Torrance, CA

      Other People Viewed

      By Subject

      78 Alzheimer's Disease Trials near San Diego, CA

      83 Alzheimer's Disease Trials near San Antonio, TX

      77 Alzheimer's Disease Trials near Los Angeles, CA

      76 Alzheimer's Disease Trials near Anaheim, CA

      18 Eczema Trials near San Francisco, CA

      16 Schizophrenia Trials near San Francisco, CA

      59 Alzheimer's Disease Trials near Phoenix, AZ

      80 Alzheimer's Disease Trials near Long Beach, CA

      Top Clinical Trials near San Francisco, CA

      Top Clinical Trials near San Francisco, CA

      Top Depression Clinical Trials near San Jose, CA

      Top Diabetes Clinical Trials near San Jose, CA

      By Trial

      KarXT + KarX-EC for Agitation in Alzheimer's Disease

      High-Fat Diet for Alzheimer's Disease

      64Cu-FBP8 PET Scan for Alzheimer's Disease

      Treadmill Training for Mild Cognitive Impairment and Alzheimer's Disease

      Care Coordination Program for Dementia

      Sleep + Cognitive Training for Cognitive Impairment

      Cognitive Behavioral Intervention for Caregiver Stress Syndrome

      Tau PET Imaging for Metabolic Health

      Acalabrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia

      Multimodal Imaging for Precancerous Oral Conditions

      18F-4FN PET Imaging Agent for Inflammation Detection

      Triplex Vaccine for CMV Prevention Post-Stem Cell Transplant

      Related Searches

      Top Alzheimers-disease Clinical Trials near Syracuse, NY

      Top Alzheimers-disease Clinical Trials near Tulsa, OK

      Top Alzheimers-disease Clinical Trials near Vancouver, WA

      Top Arthritis Clinical Trials near Austin, TX

      Top Arthritis Clinical Trials near Cincinnati, OH

      Epidural Waveform Analysis for Epidurals

      Triple Drug Therapy for Acute Lymphoblastic Leukemia

      Exercise Training for Brachial Plexus Injury

      AI Tools for Communication Research

      Dietary Intervention for Type 2 Diabetes

      Regorafenib + Lorigerlimab for Colorectal Cancer

      Pembrolizumab + Lenvatinib for Pancreatic Cancer